In T2DM, metformin has been shown to reduce levels of IL-6 [111], TNF-α, and IFN-γ, but not IL-17a [77], and it is plausible that the same might be seen in HS with a larger sample size. This evidence concerns the gene IFNG and type 2 diabetes mellitus.